1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Chronic Disease Analysis & Statistics 2021 - Europe

Chronic Disease Analysis & Statistics 2021 - Europe

Customer Support

Talk to Ahmad

+1 718 618 4302

Publishers

  • All
    • Pharma Intelligence
1-30 of 36 reports

Drug Delivery: Inhalation Devices

  • $ 4750
  • October 2019
  • 47 pages

Overview In 2018, combined sales of inhaled asthma and COPD devices in the countries covered by this analysis totaled approximately $10.4bn. Over the forecast period covered by this analysis, total sales ...

  • World
  • Spain
  • Asthma
  • Drug Delivery
  • Industry analysis
  • Asthma Prevalence

Market Spotlight: Systemic Lupus Erythematosus (SLE)

  • $ 1318
  • May 2021
  • 40 pages

This Market Spotlight report covers the Systemic Lupus Erythematosus (SLE) market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, upcoming and regulatory ...

  • World
  • Europe
  • Clinical Trial
  • Musculoskeletal Disorder
  • Industry analysis
  • Drug Approval

Market Spotlight: Fibromyalgia

  • $ 1318
  • March 2021
  • 37 pages

This Market Spotlight report covers the Fibromyalgia market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability ...

  • World
  • Europe
  • Chronic Pain
  • Clinical Trial
  • Industry analysis
  • Drug Approval

Anemia in Chronic Kidney Disease KOL Interview – US, East Coast

  • $ 599
  • June 2020
  • 16 pages

This interview with a UK-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for renal cell carcinoma. Disease stratifications ...

  • United Kingdom
  • United States
  • Renal Cancer
  • Chronic Disease
  • Industry analysis

Type 1 Diabetes KOL Interview – UK

  • $ 599
  • January 2020
  • 13 pages

This interview with a UK Key Opinion Leader (KOL) provides insight into current therapies for type 1 diabetes, as well as pricing pressures within the diabetes market, the unmet needs in type 1 diabetes, ...

  • United Kingdom
  • Type 1 Diabetes
  • Industry analysis

Rheumatoid Arthritis Payer Interview – UK

  • $ 599
  • August 2019
  • 18 pages

Overview A UK payer provides insights into pricing and reimbursement dynamics and issues surrounding biosimilars, key marketed brands, and late-phase pipeline therapies for rheumatoid arthritis.

  • United Kingdom
  • Arthritis
  • Industry analysis

Rheumatoid Arthritis KOL Interview – UK

  • $ 599
  • July 2019
  • 14 pages

A UK-based key opinion leader provides insights into prescribing habits, the most pressing unmet needs in the market, the role of biosimilars, key marketed brands, and late-phase pipeline therapies fo ...

  • United Kingdom
  • Arthritis
  • Industry analysis

Datamonitor Healthcare Chronic Heart Failure KOL Interview – Germany

  • $ 599
  • February 2019
  • 10 pages

Overview A German KOL discusses current marketed therapies and SGLT-2 inhibitors for chronic heart failure, as well as key unmet needs in this therapeutic area.

  • Germany
  • Cardiovascular Disease
  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Industry analysis

Datamonitor Healthcare Chronic Heart Failure KOL Interview – UK

  • $ 599
  • February 2019
  • 12 pages

Overview A UK KOL provides insight into marketed and pipeline therapies for chronic heart failure, as well as key unmet needs in this therapeutic area. Key marketed drugs are highlighted, including Corlano ...

  • United Kingdom
  • Cardiovascular Disease
  • Sodium-Glucose Co-Transporter 2 Inhibitor
  • Industry analysis

Finerenone

  • $ 10000
  • February 2019
  • 19 pages

Drug Overview Finerenone (Bayer) is a third-generation potent and selective oral, non-steroidal mineralocorticoid receptor antagonist (MRA). It blocks the detrimental effects due to over-activation of ...

  • Europe
  • Japan
  • Heart Failure
  • Hormone
  • Industry analysis

Datamonitor Healthcare Type 2 Diabetes KOL Interview – UK

  • $ 599
  • October 2018
  • 11 pages

Overview In this discussion with a UK KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics for patients. ...

  • United Kingdom
  • Type 2 Diabetes
  • Industry analysis

Datamonitor Healthcare Type 2 Diabetes KOL Interview – Italy

  • $ 599
  • October 2018
  • 9 pages

Overview In this interview with an Italian KOL, we cover topics related to the shift in market dynamics in recent years and what goes into the decision-making process when prescribing antidiabetics fo ...

  • Italy
  • Type 2 Diabetes
  • Industry analysis

Opsumit

  • $ 10000
  • October 2018
  • 19 pages

Drug Overview Originally developed by Actelion, Johnson and Johnson’s Opsumit (macitentan) is the follow-on product to the leading pulmonary hypertension therapy Tracleer. The drug is a next-generation ...

  • Spain
  • France
  • Respiratory Treatment
  • Hypertension
  • Industry analysis

Revatio

  • $ 10000
  • October 2018
  • 16 pages

Drug Overview Revatio (sildenafil; Pfizer) is a selective inhibitor of the PDE5 enzyme, which enhances the effect of the endogenous vasodilator, nitric oxide. The extracellular vasodilator NO activates ...

  • Japan
  • United States
  • Hypertension
  • In Vitro Diagnostic Reagent
  • Industry analysis

Breo Ellipta

  • $ 10000
  • July 2018
  • 41 pages

Drug Overview Breo Ellipta (GlaxoSmithKline/Innoviva) is a combination of fluticasone furoate and vilanterol indicated for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Fluticasone ...

  • Japan
  • Germany
  • Respiratory Disease
  • Hormone
  • Industry analysis

Daliresp

  • $ 10000
  • July 2018
  • 16 pages

Drug Overview Daliresp (roflumilast; AstraZeneca/Allergan/Takeda) is an oral phosphodiesterase 4 (PDE4) inhibitor indicated for the treatment of patients with severe chronic obstructive pulmonary disease ...

  • Japan
  • United States
  • Respiratory Disease
  • Industry analysis

Duaklir Pressair

  • $ 10000
  • July 2018
  • 18 pages

Drug Overview Duaklir Pressair ([aclidinium + formoterol]; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily fixed-dose combination of the long-acting beta 2 agonist formoterol and the long-acting ...

  • United States
  • Japan
  • Healthcare
  • Respiratory Disease
  • Industry analysis

Incruse

  • $ 10000
  • July 2018
  • 16 pages

Drug Overview Incruse (umeclidinium; GlaxoSmithKline) is a once-daily long-acting muscarinic antagonist (LAMA) indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive ...

  • United States
  • European Union
  • Respiratory Disease
  • Hospital
  • Industry analysis

Advair

  • $ 10000
  • July 2018
  • 37 pages

Drug Overview Advair ([fluticasone propionate + salmeterol]; GlaxoSmithKline) is a fixed-dose combination of an inhaled corticosteroid (fluticasone propionate) and a long-acting beta 2 agonist (salmeterol). ...

  • Europe
  • Japan
  • Pulmonary Delivery
  • Asthma
  • Industry analysis

Anoro

  • $ 10000
  • July 2018
  • 20 pages

DRUG OVERVIEW GlaxoSmithKline and Theravance (now Innoviva) developed the once-daily inhaled combination, Anoro, consisting of umeclidinium and vilanterol for the treatment of chronic obstructive pulmonary ...

  • Japan
  • European Union
  • Respiratory Disease
  • Hospital
  • Industry analysis

Cimzia

  • $ 10000
  • July 2018
  • 65 pages

Drug Overview Cimzia (certolizumab; UCB/Astellas [also marketed by Dermira in some approved indications]) is a PEGylated humanized monoclonal antibody fragment, with high affinity for both soluble and ...

  • United States
  • European Union
  • Monoclonal Antibody
  • Autoimmune Disease
  • Industry analysis

Nucala

  • $ 10000
  • July 2018
  • 27 pages

Drug Overview Nucala (mepolizumab; GlaxoSmithKline) is a humanized monoclonal immunoglobulin G1 antibody that binds to interleukin (IL)-5, which plays a significant role in the activation, proliferation, ...

  • Japan
  • United States
  • Asthma
  • Monoclonal Antibody
  • Industry analysis

Stiolto Respimat

  • $ 10000
  • July 2018
  • 21 pages

Drug Overview Stiolto Respimat ([olodaterol + tiotropium]; Boehringer Ingelheim) is a fixed-dose combination of the long-acting beta 2 agonist (LABA) olodaterol and the gold-standard long-acting muscarinic ...

  • United States
  • European Union
  • Respiratory Treatment
  • Healthcare
  • Industry analysis

Seebri Neohaler

  • $ 10000
  • July 2018
  • 17 pages

Drug Overview Novartis, under license from Vectura and Sosei, developed Seebri Neohaler, a once-daily inhaled formulation of glycopyrrolate. The once-daily long-acting muscarinic antagonist (LAMA) received ...

  • United States
  • Japan
  • Respiratory Disease
  • Healthcare
  • Industry analysis

Striverdi Respimat

  • $ 10000
  • July 2018
  • 16 pages

Drug Overview Striverdi (olodaterol; Boehringer Ingelheim) is a long-acting beta 2 agonist delivered via the Respimat inhaler. It is indicated for the once-daily maintenance treatment of airflow obstruction ...

  • Japan
  • United States
  • Respiratory Disease
  • Hospital
  • Industry analysis

Symbicort

  • $ 10000
  • July 2018
  • 30 pages

Drug Overview AstraZeneca’s Symbicort ([budesonide + formoterol]) was the second inhaled corticosteroid/long-acting beta 2 agonist (ICS/LABA) drug combination to launch on the respiratory market, starting ...

  • Japan
  • United States
  • Pharmaceutical
  • Respiratory Treatment
  • Industry analysis

Tudorza Pressair

  • $ 10000
  • July 2018
  • 17 pages

Drug Overview Tudorza Pressair (aclidinium; AstraZeneca/Circassia/Kyorin Pharmaceutical) is a twice-daily long-acting muscarinic antagonist indicated for the maintenance treatment of chronic obstructive ...

  • Europe
  • Japan
  • Respiratory Disease
  • Industry analysis

Trimbow

  • $ 10000
  • July 2018
  • 17 pages

Drug Overview Trimbow ([beclomethasone + formoterol + glycopyrrolate]; Chiesi Farmaceutici) is a fixed triple-combination product consisting of glycopyrrolate (a LAMA), formoterol (a LABA), and beclometasone ...

  • Europe
  • Generic Drug
  • Respiratory Disease
  • Industry analysis

Chronic Obstructive Pulmonary Disease Forecast and Market Analysis to 2026

  • $ 22000
  • April 2021
  • 64 pages

Disease Overview Chronic obstructive pulmonary disease (COPD) is defined by persistent airflow limitation (reduction in the ability to exhale at a normal rate and volume). While chronic and progressive ...

  • United States
  • World
  • Respiratory Disease
  • Industry analysis
  • Smoking Prevalence

Disease Analysis: Asthma

  • $ 22000
  • February 2021
  • 83 pages

Defintion Asthma is a chronic respiratory condition characterized by recurrent wheezing, coughing, and breathlessness, which occur in acute events known as exacerbations. Often triggered by factors such ...

  • World
  • Europe
  • Asthma
  • Industry analysis
  • Drug Approval
  • Asthma Prevalence
About 4000 reports

Download Unlimited Documents from Trusted Public Sources

View report >

Respiratory Disease Demographic Impact in Wales (UK)

  • October 2021
  • 9 pages
  • Wales
  • Influenza
  • Respiratory Disease
  • Industry analysis
  • Vaccination Coverage
  • Influenza Prevalence

Global Asthma Industry September 2021


Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on